Sign in →

Epic Code LAB3406 Cancer Hotspot Analysis

Test Name Alias

Cancer Hotspot Analysis | Next Gen | Ion Torrent | 703

Interface Order Alias


Quick Collect

AP Ambient

Clinical Information

Cancer Hotspot Analysis requires a small amount of tumor tissue to deep sequence 207 target regions prone to mutation (hotspots) present on 50 genes known to affect tumor growth and response to treatment. Patients with refractory and/or advanced solid tumors and those for which there is no standard treatment may benefit from this test. Guidelines are being developed in collaboration with specialists for appropriate use in each type of cancer. This assay is performed on the Ion Torrent PGM platform and has been validated in the CLIA-certified Advanced Technology Laboratory (ATL) in both research and clinical settings.


The molecular profile of a tumor specimen may provide valuable information which has the potential to guide personalized cancer treatment and provide results necessary for enrollment into various clinical trials.  Next generation sequencing and targeted molecular therapy are core components of Personalized Cancer Care within the Spectrum Health Regional Cancer Center.


Specimen Requirements

Submit only one of the following specimens:


Specimen Type:  Formalin-fixed, paraffin-embedded (FFPE) tissue (block or 10 unstained slides) accompanied by an H&E slide scribed by Pathologist and Surgical Specimen Testing order sheet

Specimen Collection:  Place specimen in 10% Formalin and order Tissue Pathology in addition to Cancer Hotspot Analysis order.



Specimen Type: Fresh tissue, flash frozen, then shipped on dry ice.

Specimen Transport Temperature

FFPE: Ambient

Frozen: On dry ice of -80oC

Specimen Stability

Laboratory Retention: Extracted DNA retained greater than 1 year.

Reflex Information

Mandatory Reflex Information:

●   All gliomas, Cancer Hotspot  Analysis

Test Frequency

Available Monday - Friday, usual TAT 10-14 days

Reference Range

An interpretative report will be provided.

Performing Department


Performing Department Laboratory Location

Corewell Health Advanced Technology Laboratory (ATL), Grand Rapids, MI


Next generation sequencing by Ion AmpliSeq technology



This test uses next generation sequencing by Ion AmpliSeq technology to detect mutations in target regions of the following genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3,  KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, and VHL. Specific regions covered by this assay in each gene can be requested.

CDM Code


Epic Test ID



LOINC code not available at this time

Reviewed Date